AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

 Phase 3 drug, Uncategorized  Comments Off on Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
May 262013
 

PREDADENANT

 

Links

http://newdrugapprovals.wordpress.com/2013/05/26/merck-provides-update-on-phase-iii-clinical-program-for-preladenant-the-companys-investigational-parkinsons-disease-medicine/

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: